Rosie Walker-Mcnair, MD
Internal Medicine · Jackson, MSNPI 1124109871
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,015 of the $7,669 with a category attached, or 78.4%. 26 manufacturers reported payments, led by Midmark Corporation at 24.3% of the total. 2025 is the largest year on record at $2,777, 2.0 times the $1,361 reported in 2019. Among internal medicine clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 217 payments — averaging $35.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Midmark Corporation$2K
- Novo Nordisk$2K
- AstraZeneca$472
- Gilead$460
- Lilly USA, LLC$439
- Pfizer$370
- plus $2K from 20 others
What the payments were for
- Travel & lodging$1,65422%
- Food & beverage$6,01578%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Midmark Corporation | 3 | $1,860 |
| Novo Nordisk | 82 | $1,671 |
| AstraZeneca | 14 | $472 |
| Gilead | 9 | $460 |
| Lilly USA, LLC | 22 | $439 |
| Pfizer | 14 | $370 |
| Novartis | 6 | $328 |
| Boehringer Ingelheim | 6 | $275 |
| Abbott | 5 | $270 |
| Amarin Pharma, Inc. | 2 | $231 |
| Merck | 11 | $214 |
| Bayer | 5 | $188 |
| GSK | 8 | $174 |
| Phathom Pharmaceuticals, Inc. | 2 | $150 |
| Astellas Pharma US Inc | 2 | $142 |
| AbbVie | 6 | $121 |
| Sanofi-aventis U.S. LLC | 7 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $35 |
| Cvrx, Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $21 |
| Viiv Healthcare Company | 1 | $19 |
| Averitas Pharma Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,669 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 112 | $120,133 |
| EliquisApixaban | 102 | $93,315 |
| JardianceEmpagliflozin | 67 | $72,942 |
| JanuviaSitagliptin Phosphate | 41 | $54,264 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 55 | $50,167 |
| RybelsusSemaglutide | 20 | $41,921 |
| LinzessLinaclotide | 38 | $37,120 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $32,936 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $32,292 |
| MyrbetriqMirabegron | 32 | $30,645 |
| FarxigaDapagliflozin Propanediol | 29 | $30,315 |
| TrulicityDulaglutide | 24 | $22,206 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $22,034 |
| XareltoRivaroxaban | 15 | $21,714 |
| JanumetSitagliptin Phos/Metformin Hcl | 23 | $19,829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,671 | $162,054132 claims |
| MerckJanuvia, Janumet Xr, Janumet | $214 | $124,259119 claims |
| PfizerEliquis | $370 | $93,315102 claims |
| Boehringer IngelheimJardiance, Tradjenta | $275 | $88,41579 claims |
| AbbVieLinzess, Synthroid | $121 | $39,26463 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $439 | $36,46336 claims |
| AstraZenecaFarxiga, Symbicort | $472 | $34,46241 claims |
| GSKTrelegy Ellipta | $174 | $32,29227 claims |
| Astellas Pharma US IncMyrbetriq | $142 | $30,64532 claims |
| NovartisEntresto | $328 | $19,19511 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $113 | $17,24111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Jackson
- Kelly WilkinsonJackson$79K
- Shanna PettieJackson$53K
- Gabriel HernandezJackson$41K
- Brendan RossJackson$19K
- Hassan CheemaJackson$16K
- James WilliamsJackson$15K
- Day LennepJackson$13K
- Carrie WynnJackson$12K
- Yanglin GuoJackson$10K
- Benedict EwaleifohJackson$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.